Artivion (AORT)

Healthcare · Medical Devices
$21.26 +0.24% on the day Market cap $1.1B 52-week range $19.16 to $48.25 Prices as of Oct 11, 2026

What the price implies

A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.

Free cash flow growth the price needs
65% a year for 10 years

At a market value of $1.1B, Artivion's free cash flow of $839,000 (fiscal 2025) would need to grow about 65% a year for the stock to be worth today's price. That is faster than the company has grown its free cash flow over the last 9 years.

Assumes a 9% discount rate and 3% growth after year 10, on free cash flow (operating cash flow minus capital spending) from Artivion's SEC filings. Change any assumption, or model revenue and margins instead, in the Modeling tab, or try your own numbers in the reverse DCF calculator.

Implied by the price64.9% a year
Free cash flow, last 9 years-26.6% a year
Revenue, same period10.5% a year
Price to free cash flow1260.0x

Fundamental grade

D

Five factors scored 1 to 9 from AORT's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.

Valuation4
Profitability2
Growth2
Financial health6
Cash efficiency4

Results from SEC filings

Fiscal years, from Artivion's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.

Fiscal year20212022202320242025
Revenue$299M$314M$354M$389M$441M
Net income-$15M-$19M-$31M-$13M$10M
Free cash flow-$16M-$16M$9M$11M$839,000
EPS (diluted)-$0.38-$0.48-$0.75-$0.32$0.21
Operating margin2.7%2.0%1.6%10.0%7.6%

Where the revenue comes from

Revenue by segments, fiscal 2025. Every breakdown, year by year.

North America$222M50%
EMEA$151M34%
APAC$44M10%
LATAM$24M5%

Superinvestors who own AORT

From each investor's latest 13F filing (what a 13F shows). 2 of the investors we track hold it.

InvestorLast quarterValue% of portfolioQuarter
Jean-Marie Eveillard
First Eagle Investment Management
Added $8M0.01%Q2 2026
Cliff Asness
AQR Capital Management
Trimmed $323,1860.0%Q2 2026

Insider buying

Open-market purchases by Artivion's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.

No open-market insider purchases of AORT in the last 12 months. Most insider activity is selling and option exercises, which aren't shown here.

Get an alert at your buy price

Pick the price you'd be interested at. We'll email you when AORT trades at or below it.

$

New accounts get 7 days of Pro, price alerts included. No card needed.

In the full deep dive

DCF fair value per share
Yearly return (IRR) at today's price
Growth implied by revenue and margins
15+ years of statements and quarters

Questions

What growth does Artivion's stock price imply?

At a market value of $1.1B, Artivion would need its free cash flow to grow about 65% a year for 10 years (discounted at 9%, 3% growth after that) to be worth today's price. Over the last 9 years its free cash flow grew -27% a year.

Are Artivion insiders buying the stock?

No open-market insider purchases of AORT in the last 12 months, according to SEC Form 4 filings.

Which superinvestors own Artivion?

2 of the superinvestors Investingly tracks hold AORT in their latest 13F, including Jean-Marie Eveillard, Cliff Asness.

Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.